Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
dc.contributor.author | De Laurentiis, Michelino | |
dc.contributor.author | Borstnar, Simona | |
dc.contributor.author | Campone, Mario | |
dc.contributor.author | Warner, Ellen | |
dc.contributor.author | Bofill, Javier Salvador | |
dc.contributor.author | Jacot, William | |
dc.contributor.author | Dent, Susan | |
dc.contributor.author | Martin, Miguel | |
dc.contributor.author | Ring, Alistair | |
dc.contributor.author | Cottu, Paul | |
dc.contributor.author | Lu, Janice | |
dc.contributor.author | Ciruelos, Eva | |
dc.contributor.author | Azim, Hamdy A | |
dc.contributor.author | Chatterjee, Sanjoy | |
dc.contributor.author | Zhou, Katie | |
dc.contributor.author | Wu, Jiwen | |
dc.contributor.author | Menon-Singh, Lakshmi | |
dc.contributor.author | Zamagni, Claudio | |
dc.date.accessioned | 2025-01-07T15:31:31Z | |
dc.date.available | 2025-01-07T15:31:31Z | |
dc.date.issued | 2022 | |
dc.identifier.doi | 10.1007/s10549-021-06374-6 | |
dc.identifier.essn | 1573-7217 | |
dc.identifier.pmc | PMC8758655 | |
dc.identifier.pmid | 34625861 | |
dc.identifier.pubmedURL | https://pmc.ncbi.nlm.nih.gov/articles/PMC8758655/pdf | |
dc.identifier.unpaywallURL | https://link.springer.com/content/pdf/10.1007/s10549-021-06374-6.pdf | |
dc.identifier.uri | https://hdl.handle.net/10668/27207 | |
dc.issue.number | 1 | |
dc.journal.title | Breast cancer research and treatment | |
dc.journal.titleabbreviation | Breast Cancer Res Treat | |
dc.language.iso | en | |
dc.organization | SAS - Hospital Universitario Virgen del Rocío | |
dc.page.number | 223-224 | |
dc.pubmedtype | Published Erratum | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 191 |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- PMC8758655.pdf
- Size:
- 311.35 KB
- Format:
- Adobe Portable Document Format